Introduction
============

Colorectal cancer (CRC) is the third most common cancer, and an important contributor to cancer mortality and morbidity worldwide [@B1]. According to the cancer statistics data of the Ministry of Health and Welfare in Korea, CRC incidence rates in 2012 were 69.3 and 45.9 per 100,000 among men and women, respectively, with rapidly increasing incidence rates in both sexes [@B2]. Although diagnosis and treatment of CRC have significantly improved over the past two decades, the survival rates in individuals with advanced CRC remain suboptimal, owing to recurrence and metastasis [@B3]. CRC progression is an intricate process associated with cumulative genomic changes [@B4]. However, underlying mechanisms that control CRC progression and metastasis remain poorly understood. Thus, it is essential to identify proteins regulating CRC progression and metastasis, which will assist in the discrimination of prognostic biomarkers to provide information regarding clinical outcomes of CRC patients, as well as in the development of novel therapeutic targets.

The Golgi apparatus is a polarized organelle, comprising three distinct cisternae: cis, medial, and trans. The Golgi complex functions as a factory in which membrane transport intermediates received from the endoplasmic reticulum (ER) are further processed and sorted for delivery to their eventual destinations: lysosomes, plasma membrane, or secretion [@B5]. Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) are a group of tail-anchored membrane proteins that play important roles in these membrane trafficking steps. SNAREs on transport vesicles (v-SNAREs) interact with SNAREs on the target membrane (t-SNAREs) in membrane docking and fusion [@B6]. In mammalian cells, at least 12 different proteins classified as SNAREs were identified in the Golgi [@B7].

The Golgi apparatus is a platform for molecular signalling between the Golgi and other organelles [@B8]. Through the organelle networking, the Golgi is involved in crucial roles in cellular activities, including stress sensing, cell death, mitosis checkpoints, and malignant transformation [@B8]. Numerous proapoptotic/autophagic factors and mitosis-related molecules are localized in the Golgi [@B9]. Therefore, the Golgi apparatus is becoming increasingly important as an anti-cancer target.

GS28 (Golgi SNARE protein, 28 kDa) has been described as a member of the SNARE protein family that plays a critical role in mammalian ER-Golgi or intra-Golgi vesicle transport [@B10], [@B11]. To date, all reports have focused on the roles of GS28 in vesicular transport, and little is known about the possible roles of this protein in pathological conditions. A recent study demonstrated that deletion mutants of GS28 in *C. elegans* demonstrated reduced seam cell numbers and a missing ray phenotype during development, suggesting that GS28 has roles in cell proliferation and differentiation [@B12]. Another report showed that mutations in GS28 lead to retinal degeneration in *Drosophila* [@B13]. However, few researches on the GS28 protein in human cancer tissues have yet been reported. We reported very recently that High nuclear expression of GS28 is associated with poor prognosis in cervical cancer patients [@B14]. The observation suggests the GS28 as a novel prognostic marker in cervical cancers.

Here, we evaluated GS28 expression in CRC in Korean patients. To our knowledge, this is the first study to assess the prognostic value of GS28 in CRC.

Materials and Methods
=====================

Patients and tumour tissues
---------------------------

A total of 230 patients (140 men and 90 women) with CRC who had undergone surgical procedures at Seoul St. Mary\'s Hospital, The Catholic University of Korea, between 2008 and 2011 were enrolled in the study. Clinicopathological data were obtained retrospectively from medical records and pathology reports. Patients ranged in age from 32 to 93 (mean, 62.3) years. Mean tumour size was 4.85 cm (range, 0.7-17.0). The study was approved by the Institutional Review Board of the Catholic University of Korea, College of Medicine (MC14SNSI0093, Oct. 6, 2014).

Tissue microarray construction and immunohistochemistry
-------------------------------------------------------

Following review of histologic sections from the 230 cases of CRC, tissue microarrays (TMAs) were constructed from paraffin-embedded blocks with a Manual Tissue Arrayer (Beecher Instruments, Inc., Sun Prairie, WI, USA) with a 2.0-mm tip. The TMA blocks were sectioned at a thickness of 4 µm, and the sections were transferred to ProbeOn Plus slides (Fisher Scientific, Pittsburgh, PA, USA) and baked for 2 hours in a dry oven at 56°C (Agilent Technologies, Santa Clara, CA, USA). Immunohistochemistry using diluted (1:500) anti-GS28 antibody (BD Biosciences, Franklin Lakes, NJ, USA) was performed according to a previously reported protocol [@B15]. GS28 expression was categorized into 4 grades according to the intensity of nuclear, cytoplasmic, and stromal staining, respectively (0, no stain; 1, weak; 2, moderate; 3, strong). Additionally, the authors evaluated CRC according to the differences between nuclear and cytoplasmic staining. Cases in which the nuclear staining score exceeded the cytoplasmic staining score were considered "nuclear predominant", and cases in which the cytoplasmic staining score exceeded the nuclear staining score, or cases with equal scores for nuclear and cytoplasmic staining, were considered "non-nuclear predominant". Positivity for EGFR expression was defined as \> 10% of tumour cells with any membrane staining above the background level. Cytoplasmic staining without associated membrane staining was considered negative, as in our previous study [@B16]. Immunohistochemical staining was independently examined by 2 pathologists (S. H. Lee and E. S. Jung).

*KRAS* mutation test
--------------------

Genomic DNA was isolated from formalin-fixed, paraffin-embedded tissue sections at a thickness of 10 μm, containing a representative tumour-rich area, with the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Tumour areas were manually microdissected from glass slides with a scalpel under a dissecting microscope in a subset of samples. We performed mutational analysis of exons 2 and 3 of *KRAS* genes using a previously described extraction method [@B17].

Statistical analysis
--------------------

The chi-square or Fisher\'s exact test was used to assess the association between GS28 expression and various clinicopathological parameters and molecular markers. The survival rate was calculated with the Kaplan-Meier method and differences were evaluated using the log-rank test. In all tests, two-sided P values \< 0.05 were considered statistically significant. Data were analysed using the SPSS statistical software version 21.0 (IBM Corp., Armonk, NY, USA) for Windows.

Results
=======

Patient characteristics
-----------------------

In the 230 patients who underwent operation, masses were right-sided and left-sided in 28.3% (65/230) and 71.3% (164/230) of patients, respectively. In one case, no information was available regarding the tumour site. Histologic examinations revealed 216 (93.9%) adenocarcinomas, 10 (4.3%) mucinous adenocarcinomas, and 4 other tumours. Patient characteristics and clinicopathological features are summarized in Table [1](#T1){ref-type="table"}.

Association of GS28 expression with clinicopathological features and molecular markers
--------------------------------------------------------------------------------------

In the normal colorectal mucosa, GS28 is expressed in the cytoplasm of the crypt epithelium with weak to moderate intensity (Figure [1](#F1){ref-type="fig"}A). In the CRC tissues, GS28 staining results were available in 214 cases. GS28 immunoreactivity was revealed in 213 cases (99.5%) of CRC. Among these, 28 cases showed weak immunopositivity, and 92 and 93 cases showed moderate and strong staining, respectively (Figure [1](#F1){ref-type="fig"}B-1D). There were 26 nuclear predominant cases and 188 non-nuclear predominant cases (Figure [2](#F2){ref-type="fig"}A and 2B). Stromal GS28 expression was demonstrated in 152 cases of CRC.

GS28 nuclear predominant immunoreactivity was significantly associated with advanced tumour stage (T stage; p = 0.045) and marginally associated with perineural invasion (p = 0.064) (Table [2](#T2){ref-type="table"}). Other clinicopathological features were not associated with GS28 expression. As stromal cells of tumour tissues are important in the progression of CRC, we evaluated the association of GS28 expression with clinicopathological parameters. Decreased GS28 expression in the stromal cells was significantly associated with lymph nodes metastasis (N stage; p = 0.036) (Table [3](#T3){ref-type="table"}). EGFR expression and *KRAS* mutations are important well-known molecular markers in CRC. However, GS28 expression was not associated with EGFR immunohistochemical positivity or *KRAS* mutation status in the current study (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}).

Prognostic values of GS28 expression in CRC
-------------------------------------------

Thirty-one patients expired during the study period. We investigated the prognostic value of GS28 with Kaplan-Meier analysis, and revealed a correlation with overall survival (p = 0.004) (Table [6](#T6){ref-type="table"} and Figure [3](#F3){ref-type="fig"}). Our results showed that the cases with GS28 nuclear predominant expression had significantly poorer overall survival than those with a non-nuclear predominant pattern. Additionally, there were no significant survival differences between CRCs with GS28 stromal expression and non-expression (data not shown). Taken together, these results indicate that GS28 nuclear predominant expression could serve as a prognostic marker for CRC.

Discussion
==========

We found that increased nuclear expression of GS28 in primary CRC tissues significantly correlated with advanced T stage tumours (p = 0.045), and decreased stromal expression of GS28 significantly correlated with advanced N stage tumours (p = 0.036). Additionally, increased nuclear GS28 expression was marginally associated with perineural invasion (p = 0.064). We were unable to find an association of cytosolic or nuclear GS28 expression with other clinicopathological parameters, such as sex, M stage, tumour differentiation, EGFR expression, or *KRAS* mutation. Therefore, a larger-scale study might be necessary to further evaluate the clinicopathological values in CRC tissues. This study is the first to examine the correlation between GS28 expression and clinicopathological parameters in CRC tissues.

The ER and Golgi apparatus are two major organelles that play important roles in the processing, sorting, and transport of newly synthesized secretory and transmembrane proteins [@B9]. The ER-Golgi network is a hub for various signalling pathways involved in crucial cellular activities, including cell death and malignant transformation [@B8]. The localization of caspase 2, Polo-like kinase 3 (Plk3), and GD3 synthase to Golgi suggested that the Golgi may be active in the crucial cellular activities [@B18]-[@B20].

GS28 is a 28 kDa membrane protein that appears to play an essential role in intra-Golgi or ER-Golgi vesicle transport [@B10]. Mammalian SNAREs known to participate in vesicular transport include GS28, Bet1, Sec22b, and syntaxin 5 [@B21], [@B22]. Very few studies have focused on the possible roles of these proteins in pathological conditions, however. Studies in *C. elegans* and *Drosophila*GS28 mutants have suggested that GS28 plays important roles in proliferation and differentiation of seam cells and in maintenance of retinal neurons [@B12], [@B13]. We reported previously that GS28 plays a protective role in hydrogen peroxide-induced cell death via inhibition of p38 MAPK in glutathione-depleted neuronal cells [@B23]. However, few researches to examine GS28 expression in human pathological tissues have yet been reported.

Recent studies have shown that the ER stress-related signalling pathways and malfunction of the Golgi apparatus are involved in cancer development [@B9], [@B24]. The present study demonstrated that increased nuclear expression of GS28 in CRC is significantly correlated with advanced T stage tumours. Considering that GS28 is a protein located in the Golgi apparatus, it can be speculated that translocation of GS28 into the nuclear compartment may be related to increases in tumour cell migration and invasion, possibly via interactions between GS28-induced nuclear functions and the Golgi apparatus. Syntaxin 17, another SNARE protein, was found to be localized in the cytoplasm, nucleus, and both in several types of cells [@B25]. Furthermore, its localization was altered in tumour cells compared with their normal counterparts, suggesting that syntaxin 17 may possess additional novel roles in cell proliferation and transformation. We observed nuclear GS28 expression in TMAs of cervical cancer, and a significant association between the high nuclear expression of GS28 and the advanced T stage tumors [@B14]. We, furthermore, demonstrated that patients with high nuclear expression of GS28 showed significantly worse overall survival and progression-free survival, compared to those with low or no nuclear expression. These suggest that the nuclear expression of GS28 protein plays important roles in the progression of CRC. However, molecular mechanisms of protein translocation and its roles remain unknown. Sun *et al.*[@B26] revealed that GS28 forms a complex with p53 and its ubiquitin ligase MDM2. They showed that overexpression of GS28 promotes cisplatin-induced apoptosis by reducing the ubiquitination and degradation of p53. In contrast, knockdown of GS28 using shRNA (short hairpin RNA) demonstrated the opposite result in response to cisplatin. These findings offer the first evidence that SNARE proteins can be involved in chemosensitivity, although these results have only been observed *in vitro*. It has not yet been confirmed that interactions among p53, MDM2, and GS28 proteins occur in the cytosolic or nuclear compartments.

We predicted conserved motifs in the GS28 protein (250 amino acids) using web-based software PROSITE and PredictProtein. Only one hit displayed in the prediction is coiled-coil helices (called SNARE motifs), which mediate the interactions between SNARE proteins. A nuclear localization signal motif is not contained in the GS28 protein. Motifs with high probability of occurrence are glycosylation sites and target sites of phosphorylation for casein kinase II (CKII), protein kinase C (PKC), and cAMP- and cGMP-dependent protein kinases. Involvement of CKII and the tumour promoter PKC as poor prognostic factors in CRC has been reported [@B27]. However, GS28 phosphorylation and its nuclear localization have not yet been reported. Further studies should be performed to confirm the molecular mechanisms of the protein kinases and the phosphorylation of GS28 in CRC.

It has been shown that 30% of patients with node-negative CRC on conventional histopathological analysis die from metastatic disease [@B28]. However, there is no standard method to identify lymphatic and blood vessel invasion, which are reliable independent prognostic factors in patients with node-negative CRC [@B28]. We identified a reverse relationship between N stage of CRC and GS28 expression in the stromal fibroblasts. Stromal cells contribute to CRC development and progression via secreting regulatory molecules [@B29]. Thus, low GS28 expression in stromal fibroblasts might be a prognostic factor for patients with node-negative CRC.

We observed an association trend of increased nuclear GS28 protein with perineural invasion in CRC. The presence of perineural invasion was suggested as an independent prognostic factor for a more aggressive phenotype and poor prognosis in CRC [@B30], [@B31]. Perineural invasion was strongly correlated with high tumour stage, poor differentiation, nodal involvement, infiltrative growth, lymphatic invasion, and venous invasion. Adjuvant therapy was suggested particularly for node-negative CRC patients with perineural invasion [@B31]. However, further studies with larger populations of CRC patients should be performed to confirm a significant association between GS28 expression and perineural invasion.

Thus, we assessed for the first time the prognostic value of GS28 in colorectal adenocarcinoma. Our findings indicate that GS28 nuclear predominant expression appears to be an independent predictor of poorer survival in patients with CRC. GS28 may be a potential novel candidate for a prognostic biomarker in the battle against CRC. Our study results provide a better understanding of the importance of GS28 in tumour development and may enable the establishment of clinically useful therapeutic targets.
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###### 

Clinicopathological data and molecular marker expression in 230 CRC patients

  Characteristics       N (%)
  --------------------- ------------
  **Sex**               
  Male                  140 (60.9)
  Female                90 (39.1)
  **Age**               
  ≤ 55 years            60 (26.1)
  \> 55 years           170 (73.9)
  **Tumour stage^a^**   
  T1                    2 (0.9)
  T2                    14 (6.1)
  T3                    157 (68.3)
  T4                    51 (22.2)
  **Nodal stage^b^**    
  N0                    86 (37.4)
  N1                    76 (33.0)
  N2                    64 (27.8)
  **Metastasis**        
  M0                    211 (91.7)
  M1                    19 (8.3)
  **Site^c^**           
  Right colon           65 (28.3)
  Left colon            86 (37.4)
  Rectum                78 (33.9)

^a^Data regarding tumour stage were unavailable in 6 cases.

^b^Data regarding nodal stage were unavailable in 4 cases.

^c^Data regarding tumour location were unavailable in 1 case.

CRC: colorectal cancer

###### 

Relationship between GS28 expression and clinicopathological parameters in CRC patients

  Parameter                 GS28 expression (n = 214^a^)   P value   
  ------------------------- ------------------------------ --------- -------------
  **Sex**                                                            0.987
  Male                      16                             116       
  Female                    10                             72        
  **Age**                                                            0.452
  ≤ 55 years                5                              49        
  \> 55 years               21                             139       
  **Tumour stage**                                                   **0.045\***
  T1, T2 or T3              16                             148       
  T4                        10                             40        
  **Nodal stage**                                                    0.654
  N0 or N1                  18                             138       
  N2                        8                              50        
  **Metastasis**                                                     0.102
  M0                        22                             176       
  M1                        4                              12        
  **Lymphatic invasion**                                             0.738
  Absent                    10                             66        
  Present                   16                             122       
  **Vascular invasion**                                              0.822
  Absent                    23                             169       
  Present                   3                              19        
  **Perineural invasion**                                            0.064
  Absent                    14                             136       
  Present                   12                             52        
  **Differentiation**                                                0.644
  Well-to-moderate          24                             178       
  Poor                      2                              10        
  **Site**                                                           0.764
  Right colon               7                              56        
  Left colon or rectum      19                             132       

^a^One case with GS28 non-immunoreactivity is included in the non-nuclear predominant subgroup.

\* Statistically significant

CRC: colorectal cancer

###### 

Relationship between GS28 expression and epidermal growth factor receptor expression, and *KRAS* mutation status in CRC patients

  Marker                GS28 expression (n = 214)   P value   
  --------------------- --------------------------- --------- -------
  ***KRAS mutation***                                         0.937
  Positive              11                          78        
  Negative              15                          110       
  **EGFR expression**                                         0.267
  Positive              17                          142       
  Negative              9                           46        

EGFR: epidermal growth factor receptor; CRC: colorectal cancer

###### 

Relationship between stromal GS28 expression and the clinicopathological parameters in CRC patients

  Parameter                 Stromal GS28 expression (n = 214)   P value   
  ------------------------- ----------------------------------- --------- -------------
  **Sex**                                                                 0.487
  Male                      96                                  36        
  Female                    56                                  26        
  **Age**                                                                 0.244
  ≤ 55 years                35                                  19        
  \> 55 years               117                                 43        
  **Tumour stage**                                                        0.863
  T1, T2 or T3              116                                 48        
  T4                        36                                  14        
  **Nodal stage**                                                         **0.036\***
  N0 or N1                  117                                 39        
  N2                        35                                  23        
  **Metastasis**                                                          0.054
  M0                        144                                 54        
  M1                        8                                   8         
  **Lymphatic invasion**                                                  0.995
  Absent                    54                                  22        
  Present                   98                                  40        
  **Vascular invasion**                                                   0.853
  Absent                    136                                 56        
  Present                   16                                  6         
  **Perineural invasion**                                                 0.631
  Absent                    108                                 42        
  Present                   44                                  20        
  **Differentiation**                                                     1.000
  Well-to-moderate          143                                 59        
  Poor                      9                                   3         
  **Site**                                                                0.563
  Right colon               43                                  20        
  Left colon or rectum      109                                 42        

\* Statistically significant

CRC: colorectal cancer

###### 

Relationship between stromal GS28 expression and epidermal growth factor receptor expression, and *KRAS* mutation status in CRC patients

  Marker                Stromal GS28 expression (n = 214)   P value   
  --------------------- ----------------------------------- --------- -------
  ***KRAS mutation***                                                 0.247
  Positive              67                                  22        
  Negative              85                                  40        
  **EGFR expression**                                                 0.476
  Positive              115                                 44        
  Negative              37                                  18        

EGFR: epidermal growth factor receptor; CRC: colorectal cancer

###### 

Kaplan-Meier analysis of overall survival in CRC patients

  Variable                           Kaplan-Meier analysis   P value             
  ---------------------------------- ----------------------- ------------------- -------------
  **GS28 nuclear predominant**       1881.42 ± 189.38        1510.24 - 2252.61   **0.004\***
  **GS28 non-nuclear predominant**   2300.14 ± 43.42         2215.04 - 2385.23   

\* Statistically significant

CRC: colorectal cancer; M: mean; SE: standard error; CI: confidence interval
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